PUBLICATIONS RELATED TO OVARIAN CANCER

 

 

 

2019

Graumann, J., Finkernagel, F., Reinartz, S., Stief, T., Brödje, D., Renz, H., Jansen, J.M., Wagner, U., Worzfeld, T., Pogge von Strandmann, E. and Müller, R. Multi-platform affinity proteomics identify proteins linked to metastasis and immune suppression in ovarian cancer plasma. Front. Oncol., in press.
 

Finkernagel, F., Reinartz, S., Schuldner, M., Malz, A., Jansen, J.M., Wagner, U., Worzfeld, T., Graumann, J., Pogge von Strandmann, E. and Müller, R. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment. Theranostics, 19: 6601-6617. 

 

Reinartz, S., Lieber, S., Pesek, J., Brandt, D.T., Asafova, A., Finkernagel, F., Watzer, B., Nockher, W.A., Nist, A., Stiewe, T., Jansen, J.M., Wagner, U., Konzer, A., Graumann, J., Grosse, R., Worzfeld, T., Müller-Brüsselbach, S. and Müller, R. Cell-type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.. Mol. Oncol. 23, 185-201. 

 

2018

Lieber, S., Reinartz, S., Raifer, H., Finkernagel, F., Dreyer, T., Bronger, H., Jansen, J.M., Wagner, U., Worzfeld, T., Müller, R. and Huber, M. (2018). Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. Oncoimmunology 7(5):e1424672. 

 

Worzfeld, T., Finkernagel, F., Reinartz, S., Konzer, K., Adhikary, T., Nist, A., Stiewe, T., Wagner, U., Looso, M., Graumann, J. and Müller, R. (2018). Proteotranscriptomics reveal signaling networks in the ovarian cancer microenvironment. Mol. Cell. Proteomics 17, 270-289.

2017

Vyas, M., Reinartz, S., Hoffmann, N., Reiners, K.S., Lieber, S., Jansen, J.M., Wagner, U., Müller, R. and Pogge von Strandmann, E. (2017). Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D down-regulation. Oncoimmunology 6(9):e1339854.

Adhikary, T., Wortmann, A. , Finkernagel, F., Lieber, S., Nist, A., Stiewe, T., Wagner, U., Müller-Brüsselbach, S. Reinartz, S. and Müller, R. (2017). Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics 18: 243.

 

Worzfeld, T., Pogge von Strandmann, E.,  Huber, M., Adhikary, T., Reinartz, S., Wagner, U. and Müller, R. (2017).  The unique molecular and cellular microenvironment of ovarian cancer. Front. Oncol. 7, 24; DOI: 10.3389/fonc.2017.00024.

Vyas, M., Müller, R. and Pogge von Strandmann, E. (2017). Antigen loss variants: catching hold of escaping foes. Front. Immunol. 8;   DOI: 10.3389/fimmu.2017.00175

Pogge von Strandmann, E., Reinartz, S., Wagner, U. and Müller, R. (2017). Tumor-host cell interactions in ovarian cancer: pathways to therapy failure. Trends Cancer 3, 137-148.

Müller, R. (2017). PPARβ/δ in human cancer. Biochimie 136, 90-99.
 

Singh R., Dhanyamraju P.K. and Lauth M. (2017). DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway. Oncotarget 8, 833-845. 

2016

 

Finkernagel, F., Reinartz, S., Lieber, S., Adhikary, T., Wortmann, A., Hoffman, N., Bieringer, T., Nist, A., Stiewe, T., Jansen, J.M., Wagner, U., Müller-Brüsselbach, S. and Müller, R. (2016). The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget 17, 75339-75352. 
 

Pogge von Strandmann, E. and Müller, R. (2016). Shipping drug resistance: Extracellular vesicles in ovarian cancer. Trends Mol. Med. 22, 741-743.
 

Reinartz, S., Finkernagel, F., Adhikary, T., Rohnalter, V., Schumann, T.,  Schober, Y., Nockher, A.W., Nist, A., Stiewe, T., Jansen, J.M., Wagner, U., Müller-Brüsselbach, S. and Müller, R. (2016). A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol. 17: 108. 
 

2015

Rohnalter, V., Roth, K., Finkernagel, F., Adhikary, T., Obert, J., Dorzweiler, K., Bensberg, M., Müller-Brüsselbach, S. and Müller, R. (2015). A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget 6, 40005-40025. 
 

Adhikary, T., Wortmann, A., Schumann, T., Finkernagel, F., Lieber, S., Roth, K., Toth, P.M., Diederich, W.E., Nist, A., Stiewe, T., Kleinesudeik, L., Reinartz, S., Müller-Brüsselbach, S. and Müller, R. (2015). The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state. Nucl. Acids. Res. 43, 5033-5051.
 

Schumann, T.,  Adhikary, T., Wortmann, A., Finkernagel, F., Lieber, S., Schnitzer, E., Legrand, N., Schober, Y, Nockher, A. W., Toth, P.M., Diederich, W.E., Nist, A., Stiewe, T., Wagner, U., Reinartz, S., Müller-Brüsselbach, S. and Müller, R. (2015). Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget 6, 13416-13433.

 

2014 and earlier

 

Reinartz, S., Schumann, T., Finkernagel, F., Wortmann, A., Jansen, J.M., Meissner, W., Krause, M., Schwörer, A.-M., Wagner, U., Müller-Brüsselbach, S. and Müller, R. (2014). Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int. J. Cancer 134, 32-42.

Baumann KH, Wagner U, du Bois A. (2012). The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol. 8, 1135-1147.

Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Oiccirillo, MC., Fossati, R., Gebski, V. and Lauraine, EP. (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and corboplatin in platinum-sensitive ovarian cacer patients, Br. J. Cancer 107, 588-591.

Reinartz, S., Failer, S., Schuell, T. and Wagner, U. (2012). CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur. J. Cancer 48: 1558-1569.

Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P.A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G., Jackisch, C., Joly, F., Brown, C., Le Fur, N., du Bois, A. (2010). Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323-29.


Reinartz, S., Pfisterer, J., Du Bois, A., Jackisch, C., Baumann, K. H. and Wagner, U. (2010). Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment. Hum. Immunol. 71, 36-44.

 

Wagner, U., du Bois, A., Pfisterer, J., Huober, J., Loibl, S., Lück, H-J., Sehouli, J., Gropp, M., Stähle, A., Schmalfeldt, B., Meier, W., Jackisch, C. (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – A phase II trial of the AGO-OVAR. Gynecol. Oncol. 105, 132-137.

Sabbatini, P., Dupont, J., Aghajanian, C., Derosa, F., Poynor, E., Anderson, S., Hensley, M., Livingston, P., Iasonos, A., Spriggs, D., McGuire, W., Reinartz, S., Schneider, S., Grande, C., Lele, S., Rodabaugh, K., Kepner, J., Ferrone, S. and Odunsi, K. (2006). Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res. 12, 5503-5510.

 

Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, A., Jacave A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., Olbricht, S. Le, T., Emerich, J., Kuhn, W., Bentley, J., Jakisch, Ch., Lück, H.-J., Rochon, J., Hayden Zimmermann, A., and Eisenhauer, E. (2006). Gemcitabine Plus Carboplatin Compared With Carboplatin In Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24, 1-10.

 

du Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A. Olbricht, S. Barats, J.-C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lück, H.-J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R. and Pujade-Leuraine, E. (2006). Addition of Epirubicin as a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarien Cancer: A Prophectively Randomized Gynecologic Cancer Intergroup Trial by the AGO-OVAR and the Groupe d´Investigateurs Nationaux pour I´Etude des Cancers Ovariens. J. Clin. Oncol. 24, 1127-11

 

du Bois, A., Belau, A., Wagner, U., Pfisterer, J., Schmalfeld, B., Richter, B., Staehle, A., Jackisch, C., Lueck, H. J., Schroeder, W., Burges, A., Olbricht, S., Elser, G., for the AGO-OVAR (2005). A phase II study of paclitaxel, carboplatin and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC  IV (AGO-OVAR protocol OVAR 8). Gynecol. Oncol. 96, 444-451.

Reinartz, S., Köhler, S., Schlebusch, H., Krista, K., Giffels, P., Renke, K., Huober, J., Mobus, V., Kreienberg, R., Dubois, A., Sabbatini, P. and Wagner, U. (2004). Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10, 1580-1587.

 

Reinartz, S., Hombach, A., Köhler, S., Schlebusch, H., Wallwiener, D., Abken, H. and Wagner, U. (2003). Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res. 63, 3234-3240.

 

Wagner, U., Köhler, S., Reinartz, S., Giffels, P., Huober, J., Renke, K., Schlebusch, H., Biersack, H.J, Möbus, V., Kreienberg, R., Bauknecht, T., Krebs, D. and Wallwiener, D. (2001). Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125 – Immune responses and survival in palliative treatment. Clin. Cancer Res. 7, 1154-1162.

OvaRA, University of Marburg, Germany

© 2017 by Rolf Müller